Home Cart Sign in  
Chemical Structure| 1629268-00-3 Chemical Structure| 1629268-00-3

Structure of ARS-853
CAS No.: 1629268-00-3

Chemical Structure| 1629268-00-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ARS-853 is an inhibitor of KRAS G12C with IC50 of 2.5 μM.

Synonyms: ARS-853

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ARS-853

CAS No. :1629268-00-3
Formula : C22H29ClN4O3
M.W : 432.94
SMILES Code : C=CC(N1CC(N2CCN(C(CNC3=CC(C4(C)CC4)=C(Cl)C=C3O)=O)CC2)C1)=O
Synonyms :
ARS-853
MDL No. :MFCD30532658
InChI Key :IPFOCHMOYUMURK-UHFFFAOYSA-N
Pubchem ID :86279165

Safety of ARS-853

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ARS-853

GPCR

Isoform Comparison

Biological Activity

Description
ARS-853 is a selective, covalent inhibitor of KRAS G12C, featuring an IC50 of 2.5 μM. By attaching to the GDP-bound form of the mutant KRAS oncoprotein, ARS-853 blocks its activation, thereby inhibiting KRAS-driven signaling pathways[1].[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
KRASCCLW (KRASG12C/C51S/C80L/C118S/Y137W) 5 μM 0.2-1 seconds and 100-1000 seconds Stopped-flow kinetic studies of ARS-853 interaction with KRASCCLW revealed fast binding (Kd = 36.0 ± 0.7 μM) and slow ligation (pKa = 8.21 ± 0.09). PMC9352912
KRAS G12C mutant 50 μM KRAS : 400 μM ARS-853 recorded every 15 or 30 minutes Monitor the binding rate of ARS-853 to KRAS G12C, showing the rate constant of ARS-853 modification was 6.40 × 10−3 min−1, almost identical to the GTP hydrolysis rate PMC10630485
HEK293 cells 10 μM 5 hours ARS853 reduced GTP-bound KRASG12C levels but had no effect on KRASG12C/A59G. PMC4955282
KRASG12C-mutant lung cancer cells (H358) 10 μM 24 hours ARS853 induced apoptosis in four KRASG12C mutant cell lines. PMC4955282
KRASG12C-mutant lung cancer cells (H358) 2.5 μM 72 hours ARS853 inhibited proliferation with an IC50 of 2.5 μM, similar to its IC50 for target inhibition. PMC4955282

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NIH 3T3 cells Cell culture treatment 25, 50, 75, and 100 μM 15 minutes Detection of intracellular oxidation of KRASG12C, showing H2O2 treatment shifts most protein to -SO2H state, blocking inhibitor binding. PMC9352912

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.55mL

2.31mL

1.15mL

23.10mL

4.62mL

2.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories